Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

This randomized phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn?t get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can?t pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.

Research Base: Children's Oncology Group
NCT ID: NCT02717507
NCI Protocol Number: COG-ALTE1621
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Carvedilol; Laboratory Biomarker Analysis; Pharmacogenomic Study; Pharmacological Study; Placebo; Quality-of-Life Assessment; Questionnaire Administration

Condition

Cancer Survivor

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP